Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Complix Receives €1.9 Million IWT Grant

Published: Tuesday, October 30, 2012
Last Updated: Tuesday, October 30, 2012
Bookmark and Share
Grant to accelerate development of Alphabodies™ against intracellular disease targets, including cancer.

Complix has announced that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

The grant will allow Complix to accelerate the development of its unique cell penetrating Alphabodies (CPABs) against a range of intracellular disease targets, including cancer.

Alphabodies represent a novel therapeutic development platform with the potential to address a vast number of disease targets that are currently considered “undruggable” by the two main classes of therapeutic drugs: small chemical drugs and therapeutic antibodies.

In particular their ability to act on intracellular protein targets represents a major medical and commercial opportunity.

During the past year, Complix has generated a wealth of data demonstrating the attractive properties of CPABs that are capable of acting on intracellular disease targets. These results show that CPABs are taken up effectively by tumor cells.

Once inside cancer cells the CPABs can act on an oncogenic target protein and block its function, thereby inducing apoptosis (cell death).

Dr Mark Vaeck, CEO of Complix, said: “We are delighted to have received this funding from IWT, which is a clear endorsement of the power of our unique CPAB platform. The results that we have generated so far indicate this platform has the potential to transform the pharmaceutical industry’s ability to address the most interesting class of potential drug targets, namely intracellular protein-protein interactions (PPIs).

“Although intracellular PPIs are known to be involved in a variety of important disease processes, such as cancer, autoimmunity, CNS and metabolic diseases, most of them have been found intractable by small chemicals or antibodies. Whilst other new technology platforms are currently also attempting to address this opportunity, we believe that Complix is well positioned to become a leading player in this next generation of so called “cross-over therapeutics”, which have the potential to boost future R&D pipelines and revitalize the growth of the pharmaceutical industry.”

Alphabodies are small single chain alpha-helical proteins that are designed by computer modeling, but are inspired by naturally existing polypeptide structures.

Alphabodies can address a diverse range of traditionally undruggable disease targets and combine the best beneficial properties of biologics and small chemical drugs, such as high specificity and potency on large protein targets, with efficient intracellular penetration and excellent stability in human serum.

Alphabodies also have the potential to be applied in other fields beyond the treatment of human disease.

Complix recently announced an important value-generating partnership with Monsanto Company that will apply Complix’ Alphabodies to create novel products for agricultural applications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Complix Launches Strategic Collaboration with Merck
Complix to receive upfront fees, research funding, and milestone payments.
Thursday, January 07, 2016
Complix Appoints Dr Yvonne McGrath as CSO
Dr McGrath will be responsible for the use of the Company´s Alphabody platform.
Saturday, May 17, 2014
Complix Raises €12 Million (US$15.5 million) in Series B Round
Financing to advance Alphabodies™, a unique class of protein therapeutics active against intracellular disease targets.
Wednesday, June 26, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!